Sierra Oncology, Inc. (NASDAQ:SRRA) was founded in 2003, formerly known as ProNAi Therapeutics, Inc. , changed to its current name in January 2017, headquartered in Vancouver, Canada, with 79 full-time employees. It is a clinical-stage drug Development company to research, develop and commercialize DNA Damage Response (DDR) therapies for cancer treatment in the United States and internationally.
Sierra Oncology, Inc. (SRRA):
Sierra Oncology is a clinical stage drug development company that promotes targeted therapies for cancer patients. Sierra Oncology has an experienced management team with a good record of success in oncology drug development, and the company is advancing a new generation of new-generation treatments for DNA damage response (DDR).
Sierra Oncology’s prime candidate product is SRA737 , an effective, highly selective, oral, biologically active, checkpoint kinase 1 (Chk1) small molecule inhibitor, which is a deoxyribonucleic acid (DNA) damage response (DDR) ) A key cell cycle checkpoint and central regulator of the network structure. Chk1 is a key regulator of cell cycle progression and DDR replication response. In cancer cells, the inherent replication stress is caused by, for example, oncogenes (such as MYC or CCNE1), genetic mutations in DNA repair mechanisms (such as BRCA1 or FANCA), gene mutations that cause cell cycle disorders (such as TP53 or RAD50) or Other genomic changes. This replication pressure leads to sustained DNA damage and genome instability, leading to an increased dependence of Chk1 on survival. Therefore, the targeted inhibition of Chk1 by SRA737 may be synthetically lethal to cancer cells with elevated internal replication stress, and can be used as a monotherapy for a series of tumor indications.
SRA737 combined with other drugs (such as other drugs that target DDR and certain chemotherapeutic agents) can also provide synergistic anti-tumor activity through various potential biological mechanisms. Importantly, the oral bioavailability of SRA737 can provide greater dosage flexibility for monotherapy and combination therapy settings than intravenously administered agents.
Sierra Oncology is seeking an innovative development plan for SRA737 and is currently evaluating two phase I/II clinical trials for patients with advanced cancer. SRA737-01 aims to evaluate the possibility of SRA737 as a monotherapy to induce synthetic lethality, while SRA737-02 aims to evaluate the combination therapy of subtherapeutic low-dose gemcitabine and SRA737.
At the same time, Sierra Oncology is conducting preclinical research to evaluate the combined use of SRA737 with other DDR targeted drugs, including poly-ADP ribose polymerase (PARP) inhibitors and immuno-oncology therapeutic drugs, which may lead to the next wave of potential clinical development Inspur may further expand its therapeutic utility.
In addition, Sierra Oncology has also developed SRA141 , an effective, selective, oral, bioavailable, small molecule inhibitor of cell division cycle 7 kinase (Cdc7). Cdc7 is a key regulator of DNA replication and participates in the DDR network, making it a compelling emerging target for potential treatment of a wide range of tumor types. SRA141 is currently undergoing preclinical research and is preparing to submit an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) at the end of 2018.